-
Corbus Pharma's Positive Phase 2 Study: Safety First
Thursday, March 30, 2017 - 2:56pm | 358Read More...Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has received a price target increase to $24 from $17 from Cantor Fitzgerald, which reiterated an Overweight rating following positive data from the company’s Phase 2 study in Cystic Fibrosis. “Treatment with anabasum at the highest dose...
-
JMP Analyst Tries To Clear Up Confusion On Corbus Pharma's Trial Data
Tuesday, November 15, 2016 - 4:16pm | 292Read More...Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) announced Monday top line results from a second stage trial of its Resunab (JBT-101) therapy for the treatment of systemic sclerosis treatment. Liisa Bayko of JMP Securities commented in a report that there appears to be some confusion...
